Doctor of Osteopathy Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Justin Li

Internal Medicine Olympia Fields, IL Doctor of Osteopathy

NPI 1689289977 CMS profile 11624866

3700 W 203Rd St Ste 301, Olympia Fields, IL 60461

Open in the dashboard

General payments

$6,203

119 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Li of Olympia Fields, IL is reported in the CMS Open Payments database as having received $6,203 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,273 89
2024 General $1,930 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Li
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Justin Li were reported at $4,273. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Justin Li Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $1,930 $154 $47–$537 $164
2025 $4,273 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Novo Nordisk Inc $930 16 payments
  2. AbbVie, Inc. $849 7 payments
  3. Lilly USA, LLC $652 26 payments
  4. Neurocrine Biosciences, Inc. $300 7 payments
  5. Amgen Inc. $286 5 payments
  6. E.R. Squibb & Sons, L.L.C. $278 5 payments
  7. Syndax Pharmaceuticals, Inc. $272 2 payments
  8. Pfizer Inc. $270 4 payments
  9. Phathom Pharmaceuticals, Inc. $260 4 payments
  10. AstraZeneca Pharmaceuticals LP $232 6 payments
  11. Other $1,873 37 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $6,203 119 payments
Products named General payments · program years 2024–2025
  1. Wegovy $582 6 payments
  2. MOUNJARO $458 20 payments
  3. QULIPTA $366 3 payments
  4. VRAYLAR $360 3 payments
  5. ZEPBOUND $349 20 payments
  6. INGREZZA $300 7 payments
  7. REVUFORJ $272 2 payments
  8. VOQUEZNA $260 4 payments
  9. Ozempic $247 4 payments
  10. UBRELVY $242 2 payments
  11. Other $3,337 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

191

Median for Hospitalist: 109

Drug cost

$1,553

Median for Hospitalist: $6,399

Branded share of claims

5.8%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amlodipine Besylate Generic 43 $297
Gabapentin Generic 15 $270
Atorvastatin Calcium Generic 33 $260
Albuterol Sulfate Hfa Albuterol Sulfate Brand 11 $184
Carvedilol Generic 11 $143
Lisinopril Generic 16 $140
Losartan Potassium Generic 20 $87
Levothyroxine Sodium Generic 16 $62
Pantoprazole Sodium Generic 14 $61
Hydrochlorothiazide Generic 12 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$20,961

Of which drugs: $3,512

Medicare patients

117

Average age 75

Services billed

203

71 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 41%
Ischemic heart disease 32%
Heart failure 27%
COPD 26%
Atrial fibrillation 21%
Chronic kidney disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 14 14 $590

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $148
$148 — —
TREMFYA
  • Janssen Biotech, Inc. $134
$134 — —
KRYSTEXXA
  • Amgen Inc. $125
$125 — —
TUKYSA
  • PFIZER INC. $122
$122 — —
LUMAKRAS
  • Amgen Inc. $121
$121 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record